Jaguar Health, Inc. (JAGX)
Market Cap | 16.67M |
Revenue (ttm) | 10.14M |
Net Income (ttm) | -38.32M |
Shares Out | 4.89M |
EPS (ttm) | -26.40 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 424,133 |
Open | 3.450 |
Previous Close | 3.480 |
Day's Range | 3.400 - 3.600 |
52-Week Range | 3.060 - 41.760 |
Beta | 0.69 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Aug 12, 2024 |
About JAGX
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief o... [Read more]
Financial Performance
In 2023, Jaguar Health's revenue was $9.76 million, a decrease of -18.36% compared to the previous year's $11.96 million. Losses were -$41.30 million, -12.97% less than in 2022.
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/y/u/press6-2497240.jpg)
Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement
JAGX's securities continue to be listed and traded on Nasdaq Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024 SAN FRANC...
![](https://cdn.snapi.dev/images/v1/j/f/press5-2490929.jpg)
Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders
Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024 Investor webcast on or before July 23 will include updates on Jaguar's...
![](https://cdn.snapi.dev/images/v1/2/b/conf6-2475449.jpg)
Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024
Investor webcast on or before July 23 will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar scientific team, patient advocates, and leading oncology ex...
![](https://cdn.snapi.dev/images/v1/6/v/press10-2469232.jpg)
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, CA / ACCESSWIRE / June 7, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective June 4, 2024, the Company granted 1,111 restricted stock u...
![](https://cdn.snapi.dev/images/v1/u/j/press4-2438007.jpg)
Jaguar Health, Inc. Announces Reverse Stock Split
Reverse split approved at April 2024 Special Meeting of Stockholders Shares of Jaguar Health common stock to begin trading on split-adjusted basis on May 23, 2024 SAN FRANCISCO, CA / ACCESSWIRE / May ...
![](https://cdn.snapi.dev/images/v1/h/b/press17-2429190.jpg)
Jaguar Health Reports First Quarter 2024 Financial Results
The combined net Q1 2024 revenue of approximately $2.4 million for prescription and non-prescription products increased approximately 20% versus net Q1 2023 revenue of $2.0 million and increased appro...
![](https://cdn.snapi.dev/images/v1/k/c/conf8-2427616.jpg)
REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
Click here to register for May 14 investor webcast Company plans to file its Earnings Report on May 14, 2024 on Form 10-Q for the quarter ended March 31, 2024 SAN FRANCISCO, CA / ACCESSWIRE / May 13, ...
![](https://cdn.snapi.dev/images/v1/e/f/press4-2421249.jpg)
Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS) in Europe
Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and SBS SAN FRANCISCO, CA / ACCESSWIRE / May...
![](https://cdn.snapi.dev/images/v1/s/r/conf13-2417958.jpg)
Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
Click here to register for May 14 investor webcast Company plans to file its Earnings Report on May 14, 2024 on Form 10-Q for the quarter ended March 31, 2024 SAN FRANCISCO, CA / ACCESSWIRE / May 8, 2...
![](https://cdn.snapi.dev/images/v1/f/a/press12-2411877.jpg)
Crofelemer, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Company's Investigational New Animal Drug Application for the Indication of General Diarrhea in Dogs
Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved anti-se...
![](https://cdn.snapi.dev/images/v1/n/w/press20-2396972.jpg)
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)
Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and short bowel syndrome (SBS) with intestin...
![](https://cdn.snapi.dev/images/v1/2/v/press6-2383023.jpg)
Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company's Expanding Focus on Cancer Supportive Care
Jaguar planning to begin commercial launch of FDA-approved Gelclair® prescription gel for oral mucositis (also called “chemo mouth”) in Q3 2024 Company to feature “ Make Cancer Less Shitty ” patient a...
![](https://cdn.snapi.dev/images/v1/y/y/press14-2378076.jpg)
Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care
Catherine Miller Collis was instrumental in bringing about Jaguar's recent in-license agreement for FDA-approved Gelclair®, a protective gel for management of oral mucositis, a common, painful, and de...
![](https://cdn.snapi.dev/images/v1/e/a/press19-2373371.jpg)
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
Jaguar planning to begin commercial launch in Q3 2024 for Gelclair®, the company's third prescription product Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse eve...
![](https://cdn.snapi.dev/images/v1/q/f/press11-2364089.jpg)
Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
Company not implementing a reverse split at this time Top line results forthcoming for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea SAN ...
![](https://cdn.snapi.dev/images/v1/j/k/press9-2360848.jpg)
Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement
Top line results forthcoming for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea SAN FRANCISCO, CA / ACCESSWIRE / April 8, 2024 / Jaguar He...
![](https://cdn.snapi.dev/images/v1/q/1/press9-2352056.jpg)
Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International
Dr. Massimo Radaelli's core focus will be on further expanding Jaguar's commercial footprint outside the U.S. Dr. Radaelli was instrumental in facilitating the recent out-license agreement with GEN fo...
![](https://cdn.snapi.dev/images/v1/m/t/press18-2349556.jpg)
Jaguar Health Reports 2023 Financial Results
Net revenue was approximately $9.8 million for the year ended December 31, 2023 versus approximately $12.0 million for the year ended December 31, 2022, a decrease of 18% Net Q4 2023 revenue of approx...
![](https://cdn.snapi.dev/images/v1/b/0/conf14-2343799.jpg)
Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates
Click here to register for April 1 investor webcast Company plans to file its Earnings Report on April 1, 2024 on Form 10-K for the year ended December 31, 2023 SAN FRANCISCO, CA / ACCESSWIRE / March ...
![](https://cdn.snapi.dev/images/v1/v/k/press7-2332958.jpg)
GEN to Commercialize Jaguar Health's Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to Market
Agreement terms to include payment of double-digit royalties to Jaguar on all Crofelemer products sold in the licensed territory SAN FRANCISCO, CA / ACCESSWIRE / March 20, 2024 / Jaguar Health, Inc. (...
![](https://cdn.snapi.dev/images/v1/i/x/press16-2290904.jpg)
Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance
SAN FRANCISCO, CA / ACCESSWIRE / February 23, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided an update regarding the status of its listing with The Nasdaq Stock Ma...
![](https://cdn.snapi.dev/images/v1/t/9/press7-2277995.jpg)
Jaguar Health Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Canalevia®-CA1 is currently FDA conditionally approved for treatment of CID in dogs and is the first and only treatment for CID in dogs to receive any type of approval from FDA By prescription only, C...
![](https://cdn.snapi.dev/images/v1/b/l/press16-2275626.jpg)
Jaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct Relief
SAN FRANCISCO, CA / ACCESSWIRE / February 14, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company is donating a supply of its novel plant-based, FDA-approved prescription drug My...
![](https://cdn.snapi.dev/images/v1/m/5/press12-2271338.jpg)
Jaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related Diarrhea
Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio cholerae Crofelemer previously granted Orphan Drug Designation by the FDA and the EMA for both shor...
![](https://cdn.snapi.dev/images/v1/z/x/conf3-2248624.jpg)
Jaguar Health to Present January 31 at The Microcap Conference and Participate in a Fireside Chat February 1 at the Lytham Partners Investor Select Conference
SAN FRANCISCO, CA / ACCESSWIRE / January 29, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present in person on January 31, 2...